Effect of Baricitinib Treatment on Peripheral Bone in RA
Status:
Active, not recruiting
Trial end date:
2021-10-11
Target enrollment:
Participant gender:
Summary
Patients with Rheumatoid Arthritis (RA) suffer systemic and peripheral bone loss. In this
study we aim to test the efficacy of in-label treatment with Baricitinib on the volumetric
bone mineral density in patients with RA over 52 weeks. Inclusion of RA patients comprises
pathologic volumetric bone mineral density measured by (High Resolution peripheral
quantitative Computed Tomomgraphy) HR-pQCT maging of finger joints.